{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:20:34Z","timestamp":1787012434674,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To quantitatively analyze change in the extent of hard exudates (HEs) following anti-VEGF therapy for diabetic macular edema (DME) and its relationships with visual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post-hoc analysis of DRCR Protocol T included 260 eyes of 260 patients. The volume of HEs was measured by automatically quantifying hyper-reflective foci (HRF) on structural optical coherence tomography (OCT) volumes using a supervised convolutional neural network architecture, \u201cDUCK-Net\u201d. HEs were quantified within the entire ETDRS grid as well as within the central subfield (CSF), inner ring (IR), and outer ring (OR) at baseline, 4, 12, 24, and 52 weeks (w) after treatment. The extent of HEs at baseline and over time was then correlated with visual acuity (VA) and retinal thickness outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following initiation of anti-VEGF therapy, HEs significantly increased from baseline (0.0293\u2009\u00b1\u20090.0455 mm3) to w4 (0.0328\u2009\u00b1\u20090.0492 mm3) and peaked at w12 (0.0350\u2009\u00b1\u20090.0513 mm3), but decreased by w52 (0.0165\u2009\u00b1\u20090.0275mm3) within the entire ETDRS region (P\u2009=\u2009&lt;\u20090.001, respectively), as well as within the OR and IR. Multiple regression analysis revealed that baseline HEs within the OR was one of the independent predictors of w52 VA (adjusted R2\u2009=\u20090.160).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following anti-VEGF for DME, HEs initially increase, followed by a subsequent decrease over one year. Greater extent of HEs at baseline is associated with worse visual outcomes at one year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-07015-0","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:57:08Z","timestamp":1762574228000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hard exudates in diabetic macular edema after intravitreal anti-VEGF therapy: a post-hoc analysis of the DRCR protocol T trial"],"prefix":"10.1007","volume":"264","author":[{"given":"Kangyeun","family":"Pak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changki","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"Srinivas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"1","key":"7015_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","volume":"102","author":"R Klein","year":"1995","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ (1995) The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology 102(1):7\u201316","journal-title":"Ophthalmology"},{"issue":"7","key":"7015_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archopht.1997.01100160043006","volume":"115","author":"DS Fong","year":"1997","unstructured":"Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis MD (1997) Subretinal fibrosis in diabetic macular edema: ETDRS report 23. Arch Ophthalmol 115(7):873\u2013877","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"7015_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","volume":"114","author":"EY Chew","year":"1996","unstructured":"Chew EY, Klein ML, Ferris FL et al (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: early treatment diabetic retinopathy study (ETDRS) report 22. Arch Ophthalmol 114(9):1079\u20131084","journal-title":"Arch Ophthalmol"},{"key":"7015_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/BF00920219","volume":"231","author":"R Phillips","year":"1993","unstructured":"Phillips R, Forrester J, Sharp P (1993) Automated detection and quantification of retinal exudates. Graefes Arch Clin Exp Ophthalmol 231:90\u201394","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7015_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10792-007-9120-3","volume":"28","author":"O Ceki\u00e7","year":"2008","unstructured":"Ceki\u00e7 O, Bardak Y, T\u0131\u011f U\u015e, Y\u0131ld\u0131zo\u011flu \u00dc, Bardak H (2008) Quantitative evaluation of reduction of plaque-like hard exudates in diabetic macular edema after intravitreal triamcinolone injection. Int Ophthalmol 28:95\u201399","journal-title":"Int Ophthalmol"},{"issue":"4","key":"7015_CR6","volume":"4","author":"F Amel","year":"2012","unstructured":"Amel F, Mohammed M, Abdelhafid B (2012) Improvement of the hard exudates detection method used for computer-aided diagnosis of diabetic retinopathy. Int J Image Graph Signal Process 4(4):19","journal-title":"Int J Image Graph Signal Process"},{"issue":"8","key":"7015_CR7","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1167\/iovs.13-11849","volume":"54","author":"M Sasaki","year":"2013","unstructured":"Sasaki M, Kawasaki R, Noonan JE, Wong TY, Lamoureux E, Wang JJ (2013) Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest Ophthalmol Vis Sci 54(8):5544\u20135550","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"7015_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/IAE.0000000000001545","volume":"38","author":"S Srinivas","year":"2018","unstructured":"Srinivas S, Nittala MG, Hariri A et al (2018) Quantification of intraretinal hard exudates in eyes with diabetic retinopathy by optical coherence tomography. Retina 38(2):231\u2013236","journal-title":"Retina"},{"issue":"4","key":"7015_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3928\/23258160-20160324-02","volume":"47","author":"Y Kim","year":"2016","unstructured":"Kim Y, Yu S-Y, Kwak HW (2016) En face spectral-domain optical coherence tomography imaging of outer retinal hard exudates in diabetic macular edema based on optical coherence tomography patterns. Ophthalmic Surg Lasers Imaging Retina 47(4):313\u2013321","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"5","key":"7015_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3341\/kjo.2019.0049","volume":"33","author":"HR Kim","year":"2019","unstructured":"Kim HR, Yoon CK, Kim HW, Pak KY (2019) New method of quantitative analysis of hard exudate using optical coherence tomography: application in diabetic macular edema. Korean J Ophthalmol 33(5):399\u2013405","journal-title":"Korean J Ophthalmol"},{"key":"7015_CR11","doi-asserted-by":"crossref","unstructured":"Yao C, Zhu W, Wang M et al (2021) SANet: a self-adaptive network for hyperreflective foci segmentation in retinal OCT images. SPIE, pp 809\u2013815","DOI":"10.1117\/12.2580699"},{"issue":"2","key":"7015_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.9.2.21","volume":"9","author":"S Xie","year":"2020","unstructured":"Xie S, Okuwobi IP, Li M, Zhang Y, Yuan S, Chen Q (2020) Fast and automated hyperreflective foci segmentation based on image enhancement and improved 3D U-net in SD-OCT volumes with diabetic retinopathy. Transl Vis Sci Technol 9(2):21\u201321","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"7015_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-025-03439-z","volume":"45","author":"Y Li","year":"2025","unstructured":"Li Y, Yu B, Si M et al (2025) Enhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning. Int Ophthalmol 45(1):79","journal-title":"Int Ophthalmol"},{"issue":"6","key":"7015_CR14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123(6):1351\u20131359","journal-title":"Ophthalmology"},{"issue":"11","key":"7015_CR15","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/IAE.0000000000003594","volume":"42","author":"G Mylonas","year":"2022","unstructured":"Mylonas G, Najeeb BH, Goldbach F et al (2022) The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: post hoc analysis of the protocol T study. Retina 42(11):2066\u20132074","journal-title":"Retina"},{"issue":"6","key":"7015_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000002633","volume":"40","author":"NM Bressler","year":"2020","unstructured":"Bressler NM, Beaulieu WT, Bressler SB et al (2020) Anti\u2013vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five DRCR retina network randomized clinical trials. Retina 40(6):1021\u20131028","journal-title":"Retina"},{"key":"7015_CR17","unstructured":"Yoon CK et al (in press). Deep learning based retinal hard exudates quantification of optical coherence tomograph. International Journal of Retina and Vitreous"},{"issue":"12","key":"7015_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.ophtha.2019.05.016","volume":"126","author":"M Nassisi","year":"2019","unstructured":"Nassisi M, Lei J, Abdelfattah NS et al (2019) OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR study. Ophthalmology 126(12):1667\u20131674","journal-title":"Ophthalmology"},{"issue":"2","key":"7015_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1167\/iovs.07-1132","volume":"49","author":"KG Csaky","year":"2008","unstructured":"Csaky KG, Richman EA, Ferris FL (2008) Report from the NEI\/FDA ophthalmic clinical trial design and endpoints symposium. Invest Ophthalmol Vis Sci 49(2):479\u2013489","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"7015_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"Network DRCR","year":"2007","unstructured":"Network DRCR (2007) Relationship between optical coherence tomography\u2013measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114(3):525\u2013536","journal-title":"Ophthalmology"},{"issue":"12","key":"7015_CR21","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ophtha.2010.03.051","volume":"117","author":"T Alasil","year":"2010","unstructured":"Alasil T, Keane PA, Updike JF et al (2010) Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology 117(12):2379\u20132386","journal-title":"Ophthalmology"},{"issue":"2","key":"7015_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.sjopt.2011.01.003","volume":"25","author":"PA Keane","year":"2011","unstructured":"Keane PA, Sadda SR (2011) Predicting visual outcomes for macular disease using optical coherence tomography. Saudi J Ophthalmol 25(2):145\u2013158","journal-title":"Saudi J Ophthalmol"},{"key":"7015_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00417-011-1774-x","volume":"250","author":"HJ Shin","year":"2012","unstructured":"Shin HJ, Lee SH, Chung H, Kim HC (2012) Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 250:61\u201370","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"7015_CR24","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaophthalmol.2015.0972","volume":"133","author":"SH Radwan","year":"2015","unstructured":"Radwan SH, Soliman AZ, Tokarev J, Zhang L, van Kuijk FJ, Koozekanani DD (2015) Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol 133(7):820\u2013825","journal-title":"JAMA Ophthalmol"},{"key":"7015_CR25","first-page":"1479","volume":"8","author":"S Jeon","year":"2014","unstructured":"Jeon S, Lee WK (2014) Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. Clin Ophthalmol 8:1479\u20131486","journal-title":"Clin Ophthalmol"},{"key":"7015_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-017-0578-0","volume":"17","author":"YU Shin","year":"2017","unstructured":"Shin YU, Hong EH, Lim HW, Kang MH, Seong M, Cho H (2017) Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. BMC Ophthalmol 17:1\u20139","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"7015_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ophtha.2014.10.028","volume":"122","author":"A Domalpally","year":"2015","unstructured":"Domalpally A, Ip MS, Ehrlich JS (2015) Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 122(4):779\u2013786","journal-title":"Ophthalmology"},{"issue":"3","key":"7015_CR28","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1167\/iovs.13-13539","volume":"55","author":"J Lammer","year":"2014","unstructured":"Lammer J, Bolz M, Baumann B et al (2014) Detection and analysis of hard exudates by polarization-sensitive optical coherence tomography in patients with diabetic maculopathy. Invest Ophthalmol Vis Sci 55(3):1564\u20131571","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"7015_CR29","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1167\/iovs.12-9950","volume":"53","author":"C Framme","year":"2012","unstructured":"Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U (2012) Behavior of SD-OCT\u2013detected hyperreflective foci in the retina of anti-VEGF\u2013treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 53(9):5814\u20135818","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"7015_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/IAE.0000000000001304","volume":"37","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic S, Bini S, Torresin T et al (2017) Hyperreflective retinal spots in normal and diabetic eyes: B-scan and en face spectral domain optical coherence tomography evaluation. Retina 37(6):1092\u20131103","journal-title":"Retina"},{"key":"7015_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2019.11.014","volume":"211","author":"S Srinivas","year":"2020","unstructured":"Srinivas S, Verma A, Nittala MG et al (2020) Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema. Am J Ophthalmol 211:183\u2013190","journal-title":"Am J Ophthalmol"},{"key":"7015_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-020-01786-2","volume":"21","author":"CK Yoon","year":"2021","unstructured":"Yoon CK, Sagong M, Shin JP et al (2021) Efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema. BMC Ophthalmol 21:1\u201310","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"7015_CR33","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1097\/IAE.0000000000000207","volume":"34","author":"SK Gelman","year":"2014","unstructured":"Gelman SK, Freund KB, Shah VP, Sarraf D (2014) The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease. Retina 34(10):2088\u20132095","journal-title":"Retina"},{"issue":"10","key":"7015_CR34","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","volume":"38","author":"SB Bressler","year":"2018","unstructured":"Bressler SB, Odia I, Glassman AR et al (2018) Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR. net protocol I 5-year report. Retina 38(10):1896\u20131904","journal-title":"Retina"},{"issue":"2","key":"7015_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1167\/iovs.17-23042","volume":"59","author":"H Lee","year":"2018","unstructured":"Lee H, Jang H, Choi YA, Kim HC, Chung H (2018) Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 59(2):715\u2013721","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"7015_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03529-8","volume":"7","author":"M Miura","year":"2017","unstructured":"Miura M, Makita S, Sugiyama S et al (2017) Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related macular degeneration using polarimetric imaging. Sci Rep 7(1):3150","journal-title":"Sci Rep"},{"issue":"1","key":"7015_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36940-5","volume":"13","author":"R-G Dumitru","year":"2023","unstructured":"Dumitru R-G, Peteleaza D, Craciun C (2023) Using DUCK-net for polyp image segmentation. Sci Rep 13(1):9803","journal-title":"Sci Rep"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07015-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:43:14Z","timestamp":1771573394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7015"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07015-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective longitudinal, Institutional Review Board-approved (University of California, Los Angeles, IRB#15\u2013000083) study was performed in accordance with the Health Insurance Portability and Accountability Act and adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for additional informed consent was waived due to the retrospective nature and use of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"SRS.Consultant (C): 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion\/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc.Recipient (R): Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc.Financial Support (F): Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}